AIDS Healthcare Foundation (AHF) and other stakeholders in the health sector have urged the European Union (EU) to stop blocking countries in the global south from accessing vaccines.Speaking on ...

A federal judge blocked parts of HHS's vaccine policy changes, siding with medical groups against Robert F. Kennedy Jr.'s agenda.

Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company focused on Shigella and ETEC vaccine development, and Serum Institute of India (SII), a Cyrus Poonawalla group company and the ...

After a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing. My tenure at these premier Wall Street ...

Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...

Specifically, Buck brews and quaffs a hazy beer that induces immunity against the BK virus, also known as human polyomavirus.

The recently unveiled America First Global Health Strategy represents a fundamental reorientation of US engagement in global health, framed as a ‘new playbook’ designed to safeguard US lives, ...

Q4 2025 earnings call: 2026 revenue guidance, COVID vaccine outlook, oncology pipeline updates, and leadership transition—read now.

The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end of 2026 to ‌start again with a new company, the biotech firm said on Tuesday. CEO Ugur ...

The move comes as BioNTech shifts to being a multiproduct commercial biotech, allowing Ugur Sahin and Özlem Türeci to transition back into research on next-generation mRNA therapeutics.

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA ...

BioNTech's two co-founders and leading executives will leave the COVID-19 vaccine maker by the end of the year to start a new venture, driving the German biotech's shares down more ...